Lv41
770 积分 2022-07-17 加入
Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer
4小时前
待确认
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
1个月前
已完结
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023
1个月前
已完结
Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors
1个月前
已完结
Advances in Targeted Therapy for Metastatic Prostate Cancer
1个月前
已完结
Inhibitors of the transactivation domain of androgen receptor as a therapy for prostate cancer
2个月前
已完结
Drugging the Undruggable: Targeting the N-Terminal Domain of Nuclear Hormone Receptors
2个月前
已完结
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer
2个月前
已完结
SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain
2个月前
已完结
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer
2个月前
已完结
皖公网安备34019202002308
